 |
18 Diseases |  |
32 Trials |
|
32 Trials |  |
839 News |  |
| «12...345678910111213...1516» |
- || GSK5101955 / GSK
Trial completion date, Trial primary completion date: Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects (clinicaltrials.gov) - Sep 7, 2020
P1, N=126, Recruiting, Sponsor: Astellas Pharma Inc
Trial completion date: Sep 2020 --> Mar 2021 | Trial primary completion date: Sep 2020 --> Mar 2021
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
PNEUMOVAX 23 nerede bulabilirim @Merck (Twitter) - Aug 31, 2020
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE). (Pubmed Central) - Aug 27, 2020
The occurrence of pneumococcal pneumonia caused by vaccine-covered serotypes dramatically decreased following the introduction of pediatric PCV13. The PCV13 serotypes were associated with pneumonia severity.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study. (Pubmed Central) - Aug 27, 2020
The PCV13 serotypes were associated with pneumonia severity. This study indicates that PPV23 with broad serotype coverage might be beneficial in preventing IPD and NBPP due to non-PCV13 serotypes in the young-elderly, with potentially increasing effectiveness in the setting of childhood PCV NIP.
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Clinical guideline, Journal: Clinical practice guidelines 2019: Indian consensus-based recommendations on pneumococcal vaccination for adults. (Pubmed Central) - Aug 26, 2020
The aim of the discussion was to lay down specific evidence-based recommendations on adult pneumococcal vaccination for the country, with a view to further ameliorate the disease burden in the country. This article presents an overview of the closed-door discussion by the expert members on clinical practice guidelines to be followed for adult pneumococcal vaccination in India.
- | risperidone / Generic mfg., Egis
Journal: Antipsychotic-induced immune dysfunction: A consideration for COVID-19 risk. (Pubmed Central) - Aug 26, 2020
Furthermore, RIS also prevented treated animals from mounting an antibody response following vaccination with Pneumovax23®. These data indicate that short-to intermediate-term exposure to clinically relevant levels of RIS dysregulate innate and adaptive immune responses, which may affect susceptibility to respiratory infections, including COVID-19.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. (Pubmed Central) - Aug 23, 2020
By risk conditions, the highest PPsV23 coverage appeared in congestive heart failure (51,909/63,596; 81.6%), chronic renal disease (122,791/158,726; 77.4%) and chronic bronchitis/emphysema (96,453/132,306; 72.9%). Maximum PCV13 coverage appeared in cirrhosis (294/7,957; 3.7%), chronic renal disease (5,633/158,726; 3.5%) and chronic bronchitis/emphysema (2,859/132,306; 2.2%).ConclusionPneumococcal vaccination coverages in Catalonian adults are suboptimal, especially for PCV13.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: The major allergen Der p 2 is a cholesterol binding protein. (Pubmed Central) - Aug 19, 2020
Three amino acid residues of Der p 2, V104, V106 and V110 are possible cholesterol binding sites, as alanine mutations of these residues showed a significant decrease in binding (p < 0.05) compared to wild-type Der p 2. These results provide the first direct experimental evidence that Der p 2 binds to cholesterol.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Phase classification: A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes (clinicaltrials.gov) - Aug 19, 2020
P4, N=100, Not yet recruiting, Sponsor: Mayo Clinic
These results provide the first direct experimental evidence that Der p 2 binds to cholesterol. Phase classification: P=N/A --> P4
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
[VIRTUAL] Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1829;
P2
The 20-valent PCV (PCV20) contains capsular polysaccharide conjugates from serotypes included in the 13-valent PCV (PCV13; Prevnar 13®) as well as 7 additional serotypes... Immune responses induced by PCV20 persisted at 12 months after vaccination in adults 60–64 years of age, further supporting the potential of PCV20 to expand serotype protection against adult pneumococcal disease.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Nationwide trends of invasive pneumococcal disease in Spain for the period 2009-2019 () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1734;
Immune responses induced by PCV20 persisted at 12 months after vaccination in adults 60–64 years of age, further supporting the potential of PCV20 to expand serotype protection against adult pneumococcal disease. Emerging serotypes are observed in Spain with the rise of serotype 24F in children and 8 in adults as a worrisome event.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Cost-Effectiveness of Implementing 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) for Adults Aged ≥19 Years with Underlying Conditions () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1140;
Adding PCV13 in series with PPSV23 for adults 19 years or older with CMC was not cost-saving. Results were sensitive to assumptions on PCV13 VE against serotype 3 disease.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
[VIRTUAL] “I don’t know”: The Typical Response When Taking Pneumococcal Immunization Histories in Kidney Transplant Candidates () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_828;
Providers documented history of pneumococcal vaccinations extremely well, ordering immunizations when necessary. This study highlights lack of portability of immunization histories in a given patient population and opportunity for improved care.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_714;
Polysaccharide pneumococcal vaccination decreases the risk of a cardiovascular event, specifically acute MI in the vaccinated population, particularly those 65 years of age and older. It would be highly beneficial to vaccinate the population who is at greater risk for cardiovascular diseases.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Missed Vaccine Opportunities During the COVID-19 Pandemic () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_659;
Due to prioritization of potential staffing shortages and clustering nursing care, an opportunity to vaccinate patients with pneumococcal and influenza vaccines was missed. It is important for health care providers to be aware of this potential opportunity for vaccination of high-risk patients in order to promote primary prevention in future waves of pandemics.
- | Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment closed: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) (clinicaltrials.gov) - Aug 13, 2020
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
It is important for health care providers to be aware of this potential opportunity for vaccination of high-risk patients in order to promote primary prevention in future waves of pandemics. Recruiting --> Active, not recruiting
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), azithromycin / Generic mfg.
Clinical, Journal: Serotype Distribution, Antimicrobial Susceptibility, and Multilocus Sequencing Type (MLST) of Streptococcus pneumoniae From Adults of Three Hospitals in Shanghai, China. (Pubmed Central) - Aug 12, 2020
The spread of international resistance clones might contribute to the increase of resistant isolates. The PPV23 could protect against most pneumococcal capsular serotypes causing infection of adults in Shanghai.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18. (Pubmed Central) - Aug 11, 2020
The incidence of pneumococcal CAP is increasing, predominantly due to NVT serotypes and serotype 3. PPV23-serotype pneumonia is more likely in adults outside currently identified clinical risk groups.
- ||||||| methotrexate / Generic mfg.
Trial completion: VACIMRA: VACcination In Methotrexate Treated Rheumatoid Arthritis Patients (clinicaltrials.gov) - Aug 9, 2020
P3, N=276, Completed, Sponsor: University Hospital, Montpellier
PPV23-serotype pneumonia is more likely in adults outside currently identified clinical risk groups. Active, not recruiting --> Completed
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Pneumococcal vaccines: Pneumococcal Conjugate Vaccine in Aging Renal Transplant (clinicaltrials.gov) - Aug 8, 2020
P1, N=57, Completed, Sponsor: VA Office of Research and Development
Active, not recruiting --> Completed Recruiting --> Completed | N=275 --> 57 | Trial completion date: Sep 2022 --> Feb 2020 | Trial primary completion date: Sep 2021 --> Feb 2020
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: Vaccination coverage with the pneumococcal and influenza vaccine among persons with chronic diseases in Shanghai, China, 2017. (Pubmed Central) - Aug 7, 2020
We found low levels with of pneumococcal vaccination, and extremely low uptake of influenza vaccination among individuals with high risk conditions in Shanghai who should be priority groups targeted for vaccination. Interventions could be designed to target groups with low uptake - like younger adults, and individuals who have not yet retired.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Factors associated with PPSV23 coverage among older adults in Japan: a nationwide community-based survey. (Pubmed Central) - Aug 6, 2020
This nationwide survey provides insight into factors that may influence PPSV23 coverage in Japanese municipalities. Reduced out-of-pocket costs and direct mail notifications to the target population were associated with higher PPSV23 coverage in Japanese municipalities.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] The 23-Pneumococcal Polysaccharide Vaccine (PPV23) importance in a Alzheimers community from the South of Brazil () - Aug 2, 2020 - Abstract #AAIC2020AAIC_3975;
This study didnt found difference for diagnosis or hospitalization for pneumonia between vaccinated and non-vaccinated patients. Future studies should explore the causes, contributing factors and impact of pneumonia prevention in this elderly population with dementia.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine. (Pubmed Central) - Jul 31, 2020
The PPVs such as PPV23 do not stimulate efficient protective immunity in children under 2 years old, while the PCVs such as PCV7, PCV10, and PCV13 that cover 7, 10, and 13 serotypes, respectively, highly protect newborns, but have some disadvantages such as complications in manufacturing, costly production, and also requires refrigeration and multiple injections...The computational studies suggested the designed vaccine as a novel construct, capable to elicit efficient humoral and cellular immunities, which are crucial for protection against S. pneumoniae. Communicated by Ramaswamy H. Sarma.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] TRIAGE OF PRIMARY HPV TESTING COMBINED WITH SELF-SAMPLING USING HPV 16/18 GENOTYPING AND/OR CYTOLOGY. A SUB-ANALYSIS OF THE GRECOSELF STUDY (ePoster) - Jul 22, 2020 - Abstract #IPVCI2020IPVC-I_894;
The optimal trade-off between sensitivity and positive predictive value (PPV) was presented by the combination of partial genotyping (HPVs 16/18) and cytology (for the non-16/18 hrHPV positive cases), i.e. sensitivity 96.55% [confidence interval (CI): 91.86-100.0%)], and PPV 23.33% (CI: 17.98-28.68). Conclusions For women residing in rural Greece, who were tested positive for hrHPV DNA with the cobas HPV test on self-collected cervicovaginal samples, the optimal triage strategy was HPV 16/18 genotyping combined with cytology for the non-16/18 hrHPV positive cases.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P4 trial, New trial: A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes (clinicaltrials.gov) - Jul 21, 2020
P=N/A, N=100, Not yet recruiting, Sponsor: Mayo Clinic
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Review, Journal: Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. (Pubmed Central) - Jul 21, 2020
Conclusions For women residing in rural Greece, who were tested positive for hrHPV DNA with the cobas HPV test on self-collected cervicovaginal samples, the optimal triage strategy was HPV 16/18 genotyping combined with cytology for the non-16/18 hrHPV positive cases. No abstract available
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Review, Journal: Outbreaks of serious pneumococcal disease in closed settings in the conjugate vaccines era, 2010-2018: a systematic review to inform national guidance in the UK. (Pubmed Central) - Jul 18, 2020
Most pneumococcal outbreaks are currently caused by vaccine-preventable serotypes, and PPV23 is the preferred vaccine in more than half the outbreaks. Early implementation of infection control measures is important, and antibiotic chemoprophylaxis should be considered for high-risk individuals.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Serotype dynamics in pneumococcal diseases and the performance of vaccination strategies for older adults in germany (Channel 5) - Jul 15, 2020 - Abstract #ERS2020ERS_4876;
Vaccination of older adults against PD is highly effective and very likely to be cost-effective in Germany. From an economic perspective, PPSV23 or SEQ would be preferred to PCV13 only.
- ||| GSK5101955 / GSK
Enrollment open: Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects (clinicaltrials.gov) - Jul 13, 2020
P1, N=126, Recruiting, Sponsor: Astellas Pharma Inc
From an economic perspective, PPSV23 or SEQ would be preferred to PCV13 only. Active, not recruiting --> Recruiting
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), atorvastatin / Generic mfg.
Clinical, Journal: Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. (Pubmed Central) - Jul 8, 2020
P1
Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: The total IgM, IgA and IgG antibody responses to pneumococcal polysaccharide vaccination (Pneumovax®23) in a healthy adult population and patients diagnosed with primary immunodeficiencies. (Pubmed Central) - Jul 8, 2020
Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines. These ranges will help to provide a framework for assessment and definition of normal response to PPV, which will facilitate clinical interpretation of a deficient polysaccharide response in those suspected of antibody deficiency.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Sex Differences in Guideline Concordant Chronic Obstructive Pulmonary Disease Diagnosis and Management in a Primary Care Setting (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_7051;
However, more evaluation is needed to assess the concordance to guidelines regarding treatment. Future interventions are needed to improve equitable COPD care delivery in primary care.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Trends in the Clinical Characteristics of Pneumococcal Pneumonia in Japanese Elderly Adults Between 2012 and 2017 (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_1200;
CONCLUSIONS Although routine vaccination of PPSV23 for elderly adults was initiated in 2014 in Japan, there was no change in the mortality of pneumococcal pneumonia patients between 2012 and 2017. In the clinical practice of elderly patients with pneumococcal pneumonia, physicians need to consider patients' age, general condition, and the existence of comorbidity disease.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Retrospective data, Journal: Altered immunogenicity of 23-valent pneumococcal polysaccharide vaccine in elderly patients with diabetes who revealed lower responses to concomitant administration of BIKEN varicella zoster vaccine: Results of post hoc analysis of a randomized double-blind trial. (Pubmed Central) - Jul 4, 2020
In the clinical practice of elderly patients with pneumococcal pneumonia, physicians need to consider patients' age, general condition, and the existence of comorbidity disease. Results suggest that concurrent administration of BVZV influenced humoral responses to PPSV23 in elderly subjects with diabetes.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Retrospective data, Review, Journal: Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. (Pubmed Central) - Jul 4, 2020
Results suggest that concurrent administration of BVZV influenced humoral responses to PPSV23 in elderly subjects with diabetes. A single dose of PCV13 elicits a better immune response among adults compared with PPV23, while having a similar safety profile to PPV23.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Relative effectiveness of revaccination with 23-valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult Aboriginal and Torres Strait Islander people, Australia. (Pubmed Central) - Jul 2, 2020
Benefits of PPV23 revaccination against IPD in this high-risk population were not demonstrated, although estimates were imprecise. Findings should be validated in other high-risk cohorts, and against all-cause pneumonia as an outcome.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion date, Trial primary completion date, Pneumococcal vaccines: Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (clinicaltrials.gov) - Jul 1, 2020
P4, N=132, Recruiting, Sponsor: Jena University Hospital
Findings should be validated in other high-risk cohorts, and against all-cause pneumonia as an outcome. Trial completion date: Sep 2020 --> Oct 2024 | Trial primary completion date: Sep 2020 --> Oct 2022
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Indirect Effects of Pneumococcal Childhood Vaccination in Individuals Treated With Immunosuppressive Drugs in Ambulatory Care: A Case-cohort Study. (Pubmed Central) - Jun 29, 2020
IPD incidences declined after PCV introduction in both immunocompetent and iatrogenically-immunosuppressed individuals, underscoring the benefit of childhood vaccination for the entire population. Still, individuals treated with immunosuppressants in ambulatory care are at increased risk of IPD caused by a more diverse group of serotypes.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Review, Journal, HEOR: Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions. (Pubmed Central) - Jun 29, 2020
Methodological approaches and assumptions in modeling VE and the indirect effects of childhood vaccination have a major impact on outcomes of decision-analytic models and cost-effectiveness estimates. Considering recently observed trends in the epidemiology of pneumococcal serotypes, there is currently inconclusive evidence regarding the cost effectiveness of pneumococcal vaccination of the elderly due to lack of studies that model key serotypes such as serotype 3 separately from other groups of serotypes.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] PNEUMOCOCCAL SEROTYPE 3 IN THE NORTHERN TERRITORY: SEVERE DISEASE DESPITE PNEUMOCOCCAL VACCINATION PROGRAMS () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_359;
Considering recently observed trends in the epidemiology of pneumococcal serotypes, there is currently inconclusive evidence regarding the cost effectiveness of pneumococcal vaccination of the elderly due to lack of studies that model key serotypes such as serotype 3 separately from other groups of serotypes. Recent severe pneumococcal serotype-3 disease in the Northern Territory was associated with a phylogenetic cluster frequently detected in IPD since 2013, but infrequently detected in carriage.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] UNMET NEED IN CONTROLLING INVASIVE PNEUMOCOCCAL DISEASE (IPD) AMONG CANADIAN OLDER ADULTS IN THE CONTEXT OF THE CURRENT AND POTENTIAL FUTURE PNEUMOCOCCAL VACCINATION PROGRAMS () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_344;
Initial decline in PCV13-type IPD, likely an indirect effect of pediatric program, leveled off in recent years supporting the need for broad PCV13 use in older adults. PCV20, which shares 19 serotypes with PPV23, could address limitations of the PPV23 program in the ability to control vaccine-type IPD.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] PNEUMOCOCCAL VACCINE IN RENAL TRANSPLANT :DISTANCE OF GUIDELINES FROM REALITY () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_328;
PCV20, which shares 19 serotypes with PPV23, could address limitations of the PPV23 program in the ability to control vaccine-type IPD. Pneumococcal vaccine immunogenicity appearance and duration in renal transplantation is not compatible with guidelines recommendations , immunogenicity decrease after first year dramatically in spite of using newer generation and booster doses ,we are face to questions such as the best time of installation,how can enhance immunogenicity and the best vaccine type that we can use .
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] ECONOMIC EVALUATION OF PNEUMOCOCCAL RISK GROUP VACCINATIONS IN FINLAND () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_307;
Life expectancy affects significantly the cost-effectiveness results among the elderly. When evaluating the cost-effectiveness of pneumococcal risk group vaccinations it’s important to consider the high all-cause mortality among the elderly at-risk population.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] COST-EFFECTIVENESS OF PCV13 IN IMMUNOCOMPETENT US ADULTS AGED 65 YEARS: IMPORTANCE OF VACCINE EFFECTIVENESS AGAINST SEROTYPE 3 () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_305;
Cost-effectiveness of PCV13 in immunocompetent US adults aged 65 years varies considerably under alternative assumptions regarding VE-PCV13 versus ST3. When assuming a reasonable value for VE-PCV13 versus ST3, results suggest that PCV13 provides acceptable value for money in this patient population.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] EXPLORATORY COST-EFFECTIVENESS ANALYSIS OF IN-DEVELOPMENT AND HYPOTHETICAL HIGHER-VALENCY PNEUMOCOCCAL CONJUGATE VACCINES IN OLDER ADULTS: BARKING UP THE WRONG TREE? () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_292;
In exploratory analyses, PCV15/PCV20 may not be economically reasonable in older adults, regardless of serotype effectiveness assumptions, particularly when potential indirect effects were considered. Adult vaccines containing higher-risk serotypes not contained in childhood vaccines may be more promising.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] EPIDEMIOLOGY OF SEROTYPES OF S. PNEUMONIAE IN PATIENTS OLDER 18 YEARS IN RUSSIA () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_261;
Vaccine serotypes of S. pneumoniae are dominating in 18+ patients in Russia. Nevertheless, we can see the reduction of PCV’s coverage of serotypes in patients with pneumonia and IPD (less than 60%).
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] EFFECTIVENESS OF INFLUENZA VACCINATION AGAINST INVASIVE PNEUMOCOCCAL DISEASE IN THE ELDERLY ≥65 YEARS ELIGIBLE FOR VACCINATION IN ENGLAND AND WALES () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_258;
IPD cases were extracted from surveillance database with information on serotype, specimen date, age, clinical conditions, sex, PPV23 and Influenza vaccination dates... Since VE against Influenza was 29% overall and 56% against H1N1 in the elderly in 2015/16 in UK, a very strong association between Influenza and IPD would be needed to have a 27% VE against IPD.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] CANADIAN ADULTS 50-64 YEARS OF AGE CONTRIBUTE SUBSTANTIALLY TO THE CASES OF INVASIVE PNEUMOCOCCAL DISEASE (IPD) POTENTIALLY PREVENTABLE BY THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_234;
In 2017, 23% and 34% of IPD in these two cohorts, respectively, was of PCV13-type. These findings support the rationale for intensified PCV13 immunization efforts in both age groups.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] EFFECTIVENESS OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV-23) IN THE PREVENTION OF HOSPITALIZATIONS DUE TO VACCINE-TYPE PNEUMOCOCCAL PNEUMONIA () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_226;
PPV-23 does not protect elderly patients against hospitalization for VT-CAP. More effective prevention strategies are necessary.